Clinical pharmacokinetics and metabolism of bevantolol.
Bevantolol (the hydrochloride salt) has pharmacokinetic properties that are clinically advantageous. Bevantolol is well absorbed orally (greater than 70%); and the systemic bioavailability is 60%. Peak plasma concentrations are achieved 1 to 2 hours following an oral dose. Elimination is first-order with an average elimination half-life of 1.5 hours. Bevantolol exhibits linear pharmacokinetics within the therapeutic range (100 to 400 mg) with no change in half-life with chronic dosing. These properties result in predictable plasma levels and predictable drug response.
Latts
J R
JR
D000319:Adrenergic beta-Antagonists / Q000378:metabolism*; D000368:Aged; D000375:Aging; D001682:Biological Availability; D005260:Female; D006801:Humans; D007408:Intestinal Absorption; D007700:Kinetics; D008297:Male; D011412:Propanolamines / Q000378:metabolism*; D012737:Sex Factors; D014018:Tissue Distribution
D000319:Adrenergic beta-Antagonists; D011412:Propanolamines; C021148:bevantolol